Literature DB >> 22915060

Randomization and statistical power: paramount in trial reproducibility (even for rare cancers).

Laurence H Baker1, John J Crowley, Robert G Maki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22915060      PMCID： PMC3448404          DOI： 10.1634/theoncologist.2012-0209

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  26 in total

1.  Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors.

Authors:  J Maurel; M Zorrilla; T Puertolas; A Antón; A Herrero; A Artal; V Alonso; J Martinez-Trufero; M M Puertas
Journal:  Anticancer Drugs       Date:  2001-10       Impact factor: 2.248

Review 2.  [Gemcitabine in advanced stage soft tissue sarcoma: a phase II study].

Authors:  A Amodio; S Carpano; C Manfredi; G Del Monte; L Di Lauro; T Gionfra; F Conti; G Paoletti; M Lopez
Journal:  Clin Ter       Date:  1999 Jan-Feb

3.  Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.

Authors:  O Merimsky; I Meller; G Flusser; Y Kollender; J Issakov; M Weil-Ben-Arush; E Fenig; G Neuman; D Sapir; S Ariad; M Inbar
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

4.  Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.

Authors:  S R Patel; V Gandhi; J Jenkins; N Papadopolous; M A Burgess; C Plager; W Plunkett; R S Benjamin
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

5.  Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.

Authors:  J Verweij; S M Lee; W Ruka; J Buesa; R Coleman; R van Hoessel; C Seynaeve; E D di Paola; M van Glabbeke; D Tonelli; I R Judson
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

6.  Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.

Authors:  E Späth-Schwalbe; I Genvresse; A Koschuth; A Dietzmann; R Grunewald; K Possinger
Journal:  Anticancer Drugs       Date:  2000-06       Impact factor: 2.248

7.  Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

Authors:  L Svancárová; J Y Blay; I R Judson; Q G C M van Hoesel; A T van Oosterom; A le Cesne; H J Keizer; C Hermans; M van Glabbeke; J Verweij; P C W Hogendoorn; O S Nielsen
Journal:  Eur J Cancer       Date:  2002-03       Impact factor: 9.162

8.  Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).

Authors:  Patricia Pautier; Anne Floquet; Nicolas Penel; Sophie Piperno-Neumann; Nicolas Isambert; Annie Rey; Emmanuelle Bompas; Angela Cioffi; Corinne Delcambre; Didier Cupissol; Françoise Collin; Jean-Yves Blay; Marta Jimenez; Florence Duffaud
Journal:  Oncologist       Date:  2012-08-20

9.  Phase II trial of gemcitabine in advanced sarcomas.

Authors:  Scott Okuno; John Edmonson; Michelle Mahoney; Jan C Buckner; Stephen Frytak; Evanthia Galanis
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

10.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Authors:  Martee L Hensley; Robert Maki; E Venkatraman; Gennifer Geller; Meghan Lovegren; Carol Aghajanian; Paul Sabbatini; William Tong; Richard Barakat; David R Spriggs
Journal:  J Clin Oncol       Date:  2002-06-15       Impact factor: 44.544
View more
  1 in total

1.  Design analysis indicates Potential overestimation of treatment effects in randomized controlled trials supporting Food and Drug Administration cancer drug approvals.

Authors:  Emily M Lord; Isabelle R Weir; Ludovic Trinquart
Journal:  J Clin Epidemiol       Date:  2018-07-02       Impact factor: 6.437
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.